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CPT-11 (irinotecan hydrochloride, 7-ethyl-10-(4-[1-piperidino]-1-
piperidino)-carboxyloxy-camptothecin) is a water-soluble deriva-
tive of camptothecin (Sawada et al, 1991). CPT-11 stabilizes the
nuclear topoisomerase I/DNA complex leading to an accumulation
of single-strand breaks in DNA and to cell death (Kawato et al,
1991; Rivory, 1996a; Takasuna et al, 1996). Enhanced lipid
peroxidation may also contribute to CPT-11-induced cell death
(Sadzuka and Hirota, 1997). Clinically, CPT-11 has been used to
treat a number of cancer types including colorectal, breast,
cervical, ovarian, gliomas, lymphoma and small-cell and non-
small-cell lung (Rothenberg, 1996; Gerrits et al, 1997; Colvin et
al, 1998). CPT-11 was found to be the most effective chemothera-
peutic agent in our recent comparison of the efficacies of doxoru-
bicin, cisplatin, CPT-11 and topotecan against xenografts of colon
(SW 620, COLO 205 and HT29), lung (H 460, A549, H 226) and
breast (MDA-MB 231, MCF7 and T47D) cancer cell lines in nude
mice (manuscript in preparation).
In a previous study (Hardman et al, 1997), we used 19% (w/w)
dietary fish oil to increase the efficacy of edelfosine, an ether-lipid
cancer chemotherapeutic drug. One of the proposed mechanisms
of fish oil’s ability to increase the efficacy of edelfosine was by
enhancing lipid peroxidation in the tumour to cytotoxic levels
(Hardman et al, 1997). Since CPT-11 treatment has also been
reported to increase lipid peroxidation (Sadzuka and Hirota,
1997), we questioned whether the addition of fish oil to the diet
of cancer bearing mice prior to treatment with CPT-11 would
increase the efficacy of CPT-11 against the tumour. To increase the
clinical relevance of the current study, fish oil was incorporated at
3% or 6% w/w of the diet, so that the quantity of fish oil fed to the
mice would approximate levels which humans can consume.
An important consideration prior to recommendation of any
drug treatment is the evaluation of toxic side-effects to the host.
The major dose-limiting toxicity of CPT-11 in humans has been a
debilitating, delayed diarrhoea (Rivory, 1996a; Rothenberg, 1996;
Kase et al, 1997b; Sakai et al, 1997). Histopathological changes in
the small and large intestines, including degeneration and necrosis
of villi and crypt cells (Ikuno et al, 1995; Kase et al, 1997b; Cao
et al, 1998; Shinohara et al, 1998) have been associated with the
diarrhoea resulting from CPT-11 administration in preclinical
animal studies (Cao et al, 1998). Strategies that reduce the
histopathological damage to the small and to the large intestine
might be expected to increase the clinical usefulness of CPT-11.
In the current report, tumour growth curves revealed that
supplementation of the diet with either 3% or 6% w/w fish oil fed
prior to and during treatment with CPT-11 enhanced regression of
the MCF7 human breast cancer xenografts in nude mice.
Evaluation of side-effects of CPT-11 treatment showed that CPT-
11 treatment caused the same body weight loss whether the mice
were fed the corn oil or the fish oil diets; however, histopatholog-
ical damage to the small and large intestine was reduced when the
CPT-11 treated mice consumed dietary fish oil. Thus, consumption
of low levels of dietary fish oil increased the efficacy of CPT-11
against the tumour and decreased the histopathological damage to
the intestines caused by CPT-11 treatment. In this preclinical
study, supplementation of the diet with low levels of fish oil
proved to be an effective adjunct to chemotherapy with CPT-11
and may also be an effective adjunct to cancer chemotherapy with
CPT-11 in humans.
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Summary The cancer chemotherapeutic efficacy of the topoisomerase I inhibitor, CPT-11 (irinotecan) is often limited by the induction of
severe delayed diarrhoea. In animal studies, CPT-11 use is associated with histopathological damage to the mucosa of the small and large
intestines. Results from the present study demonstrate that 60 mg CPT-11 per kg body weight (i.v. q4d 3 6) halted the growth, but did not
cause significant regression, of MCF7 human breast carcinoma xenografts in mice fed a diet containing 7% corn oil. However, when the diet
of the MCF7-bearing mice was supplemented with 3% or 6% fish oil, the same CPT-11 treatment caused significant regression of the MCF7
xenograft. Histomorphometric analyses of intestinal mucosa of mice treated with CPT-11 and fed the diet containing 7% corn oil indicated that
treatment with CPT-11 induced structural changes in the intestinal mucosa which persisted at least 5 days after the last dose of CPT-11. The
intestinal mucosal architecture of mice that were treated with CPT-11 and fed the diets containing fish oil was largely unchanged from the
architecture of the group of mice which did not receive CPT-11. These findings indicate that fish oil supplements may be a useful adjunct to
CPT-11 treatment. © 1999 Cancer Research Campaign
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METHODS AND MATERIALS
Tumour cells
MCF7 human breast cancer cells (American Type Culture Collection,
Rockville, MD, USA) were cultured for injection in nude mice. The
culture medium was M3:10TM (INCELL Corporation, LLC).
Mice
Twenty female nude mice (nu/nu, Harlan Sprague Dawley,
Madison, WI, USA) 6 weeks old were used in this study. Each
mouse was numbered for identification. The mice were allowed to
acclimate for 1 week before beginning the experiment. Mice were
housed under aseptic conditions (positive air pressure in a desig-
nated nude mouse room, cages, bedding and water cages and
microisolator tops) in a temperature (24°C) and light controlled
(12 h light per day) room. All mouse handling was carried out
under a laminar flow hood. All animal use and handling was
approved by the UTHSCSA Institutional Animal Care and Use
Committee before commencing the experiment. The animal care
facilities are accredited by the American Association for the
Accreditation of Laboratory Animal Care.
Oestrogen supplementation
Female nude mice produce inadequate oestrogen to support the
growth of MCF7 cells. Therefore, the mice were given injections
of b-oestradiol (Sigma, St Louis, MO, USA) dissolved in pure
sesame oil (0.1 mg per 0.05 ml sesame oil per mouse, subcuta-
neously (s.c.) over rump) beginning 1 day before the injections of
MCF7 cells and at weekly intervals thereafter until the end of the
experiment.
Preparation of cells
Cultured MCF7 cells were harvested, rinsed then suspended in
serum-free M3D base culture medium (INCELL Corporation,
LLC). Cells in suspension were counted using a haemocytometer
and the cell count was adjusted to 108 ml–1. The suspension was
kept well mixed during the time of injection. MCF7 cells (5 3 106
cells in 0.05 ml of serum-free media) were injected s.c. on the
upper back of each mouse.
Experimental design
Mice were fed Harlan Teklad LM-485 Mouse Chow diet while the
tumours were allowed to grow to about 5 mm diameter. This
allowed the tumours to become established as growing tumours
in the host mice before feeding of the experimental diets. The
tumour-bearing mice were then divided into four groups. One
group of five mice remained on the chow diet and did not receive
CPT-11 (untreated, normal control). Three groups were placed on
diets, based on the AIN-76A diet, modified to contain 7% total fat.
The 7% total fat for each of the three experimental diets was
divided as follows:
1. 7% corn oil, 0% fish oil (control diet with CPT-11)
2. 4% corn oil, 3% antioxidant-free fish oil (3% fish oil with
CPT-11)
3. 1% corn oil, 6% antioxidant-free fish oil (6% fish oil with
CPT-11).
The compositions of the experimental diets are shown in Table
1. Fish oil was purchased and used without added antioxidant
specifically to exploit the potential to enhance lipid peroxidation,
as in our previous study (Hardman et al, 1997). The corn oil and/or
fish oil diets were prepared weekly, daily portions for each cage
were packaged individually and the packages were stored in sealed
containers at –20°C to suppress spontaneous lipid peroxidation.
The corn oil and the fish oil diets were replaced daily. The mice
were maintained on these diets for 10 days before beginning treat-
ment with CPT-11.
Drug preparation
CPT-11 was obtained as irinotecan hydrochloride (Pharmacia &
Upjohn, Kalamazoo, MI, USA). It was prepared, according to
manufacturer’s directions, to duplicate the clinical formulation
(CamptosarTM). The prepared CPT-11 contained: 20 mg ml–1
irinotecan hydrochloride, 45 mg ml–1 sorbitol (Sigma, St Louis,
MO, USA) and 0.9 mg ml–1 lactic acid (Sigma, St Louis, MO,
USA) and was pH adjusted to 3–3.8. The solution was warmed in
a 100°C water bath to dissolve the CPT-11. A dose of 60 mg CPT-
11 per kg body weight (about 0.08 ml per 28 g mouse) was
injected into the lateral tail vein of each treated mouse, once each
4 days for 6 weeks.
Tumour and body weight measurements
Lengths and widths of tumours and body weight were measured
three times weekly. Measurements were entered directly into an
Table 1 Composition of the experimental diets by weight per cent
(g per 100 g of food)
Ingredient g per 100 g of food
aTotal oil 7.0
Sugar 48
Casein 20
Cornstarch 15
AIN-76 vitamin mixa 1.0
AIN-76 mineral mixa 3.5
Choline bitartrate 0.2
DL-methionine 0.3
Cellulose 5
Total 100.0
Composition of the diets by % caloriesb
Protein 20.2
Carbohydratec 63.9
Fat 15.9
bEnergy content of each diet, kcal/g 3.95
aTotal fat was 7%. Diet types included 7% corn oil (control diet with CPT-11)
or 4% corn oil, 3% antioxidant-free menhaden fish oil (3% fish oil diet) or 1%
corn oil, 6% antioxidant-free menhaden fish oil (6% fish oil diet). bCaloric
content is calculated at 4 kcal/g for protein and carbohydrate and 9 kcal/g for
fat. cThe % of calories from carbohydrate include the calories from sucrose,
cornstarch and sucrose in the vitamin and mineral mix. Diet components and
chemicals – purified high nitrogen casein, pure corn starch, Alphacel (non-
nutritive bulk cellulose) AIN-76 vitamin mixture, AIN-76 mineral mixture and
choline bitartrate (99% pure) were obtained from ICN Nutritional
Biochemicals, Cleveland, Ohio. Imperial brand (Sugarland, TX) extra fine
pure cane sugar and 100% pure corn oil (Wesson) were purchased locally.
DL-methionine (cell culture, Mr 149.2), antioxidant free menhaden fish oil and
ferric citrate were purchased from Sigma, St. Louis, Missouri.442 WE Hardman et al
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Excel spreadsheet. Tumour sizes were calculated using the
formula for the volume of a prolate spheroid: V = 4/3 * 3.14 * L/2
*W/2 * D/2. The width measurement was used as the depth of the
tumour. This shape was a good approximation of the shape of the
tumours.
The experiment was terminated 28 days after the initiation of
CPT-11 treatment. The mice were anaesthetized using a keta-
mine/S. A. rompun mixture (0.2 cc per 25 g weight, IM; prepared
by our Laboratory Animal Resources veterinarian), then killed by
cervical dislocation.
Necropsy and tissue processing
Tumours, liver, small and large intestines were removed at
necropsy. Tumours were fixed in Omnifix® (Melville, NY, USA)
for later analysis. Omnifix® is an alcohol-based, proprietary
formula fixative which does not cross-link antigen epitopes as
does formalin. A portion of the liver was flash frozen in liquid
nitrogen for later analyses. A 1-cm segment of each small intestine
and a 1-cm segment of each large intestine were consistently
removed from regions 2 cm from the stomach/duodenum junction
or 4 cm from the anus respectively. These tissue segments were
placed on a small piece of cardstock, split longitudinally, spread
and affixed mucosal side up to the card. Card and tissue were then
placed in Omnifix® for fixation. After fixation, tissues from indi-
vidual mice were placed in a tissue cassette and processed for
embedding in paraffin blocks. Small and large intestine segments
were oriented on-edge in the paraffin blocks so that complete
longitudinally sectioned crypts would be seen on microscope
slides. Four-micrometer-thick sections were cut and placed on
slides. One set of slides was stained using haematoxylin and eosin
(H&E), a second set of slides was stained by the periodic acid-
Schiff (PAS) reaction and counterstained with haematoxylin to
identify mucin in goblet cells. Slides were coded and evaluated by
an observer blinded to the group of origin of each slide.
Products of lipid peroxidation
At a later date, frozen livers were thawed and homogenized individ-
ually at 4°C using a Polytron homogenizer. The total protein content
of an aliquot of the whole specimen homogenate was analysed by
the method of Bradford (Bradford, 1976) using the Bio-Rad protein
assay (micro-method). The thiobarbituric acid reactive substances
(TBARS) assay was used to estimate lipid peroxidation on the
remainder of the homogenate. Malondialdehyde and other products
of lipid peroxidation can be estimated spectrophotometrically at
535 nm after reaction with thiobarbituric acid to obtain an index for
lipid peroxidation (Esterbauer et al, 1991). We realize that TBARS
does not measure all products of lipid peroxidation and that there
may be minor interference by other substances (sugars, amino acids,
etc.), however, this simple inexpensive test does provide a good esti-
mate of changes in overall lipid peroxidation of tissues. The
absorbance values obtained were compared against a standard curve
of known concentrations of malondialdehyde and normalized by
protein content of the specimen. The results were reported as nmol
of TBARS per mg of protein.
Histological analyses of duodenum and colon
Only complete midaxially sectioned crypts in duodenum and colon
on H&E-stained slides were selected for analyses of crypt height,
and number and location of mitotic and apoptotic cells. Complete
crypts were defined as those with:
1. the crypt base at the muscularis mucosa
2. an open lumen from mouth to base
3. a single column of epithelial cells up each side of the crypt.
Crypt height was defined as the number of cells in a single
column from the centre of the base to the mouth of the crypt in
complete midaxially sectioned crypts. Mitotic and apoptotic
figures in the duodenum were identified on H&E-stained slides.
The position of each mitotic or apoptotic figure in number of cells
from the centre of the crypt base were recorded. Apoptotic events
were identified by the morphological parameters of nuclear
marginalization of the chromatin, condensation of the cytoplasm,
cell shrinking, membrane blebbing and, finally, fragmentation of
the cell into apoptotic bodies (Potten, 1992; Barnes et al, 1997).
PAS-stained slides were used to determine the distribution of
mucin containing goblet cells. Complete, midaxially sectioned
crypts in sections of duodenum and colon were identified then the
location of each PAS-stained cell (PAS+) in number of cells from
the centre of the crypt base to the crypt mouth was recorded.
Table 2 Slopes of the linear regression analyses of mouse body weights
(g change per day) following dietary modification and CPT-11 treatmenta
Diet Days 1–14 after dietary Days 14–33 after dietary
modification (mean ± SD) modification (mean ± SD)
Control, no –0.049 ± 0.028 no CPT-11,  0.22 ± 0.024
CPT-11
7% Corn oil –0.010 ± 0.042 with CPT-11, –0.047 ± 0.020
3% Fish oil 0.064 ± 0.048 with CPT-11, –0.116 ± 0.020
6% Fish oil 0.038 ± 0.036 with CPT-11, –0.067 ± 0.016
aDuring days 1–14, no slope was significantly different from a slope of zero
(no change in body weight per day). During the time of CPT-11 treatment
(60 mg kg–1 body weight CPT-11 each 4 days) all CPT-11-treated groups
showed significant weight loss. ANOVA followed by SNK multiple range test
of the slopes showed that there was no significant difference in the slope
(weight loss) due to the diet of the CPT-11-treated mice.
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Figure 1 Growth of MCF7 human breast cancer xenografts in nude mice.
Mice with growing tumours were divided into four groups (5 mice per group)
and fed chow (control, no CPT-11) or modified AIN-76A diets containing 7%
corn oil; 3% fish oil with 4% corn oil; or 6% fish oil with 1% corn oil. After 2
weeks on the diet, CPT-11 treatment (60 mg/kg body weight, i.v. q4d 3 6)
was initiated. The mean tumour volume for each group was normalized to
zero at the beginning of the CPT-11 treatment. Mice were killed 5 days after
the sixth injection of CPT-11. The results of statistical analyses of the change
in tumour size are reported in the textFish oil, CPT-11 and breast cancer 443
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The thickness of the muscularis mucosa was measured on the
H&E-stained sections using a calibrated ocular micrometer.
Statistical analyses
Mean body weights during the experiment were analysed by linear
regression analyses using PRISM®. Body weight data were divided
into two linear regression analyses: (1) the time before the initiation
of CPT-11 and (2) the time after initiation of CPT-11 to determine
the effect of the diet and of the CPT-11 on the rate of change of the
mean body weights of each group of mice. Significant differences
between the slopes of the linear regression analyses either before or
after CPT-11 treatment were determined by analysis of variance
(ANOVA) followed by a Student–Newman–Keuls (SNK) multiple
range test using PRISM® software.
The mean tumour volume for each group was normalized to
zero at the beginning of the CPT-11 treatment. Mean tumour
growth curves were generated for each group and linear regression
analysis was used to assess the tumour growth rate of each group.
A significant positive slope indicated tumour growth, a significant
negative slope indicated tumour regression and a non-significant
slope indicated no growth. Analyses for differences between
slopes of the regressions of the mean tumour volumes of each
group were performed by PRISM® (Graphpad Software, San
Diego, CA, USA) using the general linear model to generate an
ANOVA. An SNK multiple range test was used to determine
which slopes were significantly different against the null hypoth-
esis that there was no difference between the slopes. A probability
value (P) ≤ 0.05 was used to indicate that the tumour growth rates
represented by the slopes were significantly different.
ANOVA followed by SNK was used to determine differences
between groups in TBARS in the livers.
Kolmorogov–Smirnov (K–S) tests for normality showed that
the distributions of the heights of mitotic and apoptotic figures in
duodenum crypts differed significantly from a normal distribution.
However, the distribution of the square root transformed heights of
mitotic and apoptotic figures did not differ significantly from a
normal distribution. Thus, a parametric ANOVA followed by an
SNK was used to test for differences between the means of the
square root transformed heights of mitotic figures or of apoptotic
figures.
The K-S test showed that the crypt heights and the locations of
PAS-positive cells along the length of the crypt were not signifi-
cantly different from a normal distribution, thus transformation
was not needed prior to ANOVA of crypt heights or of means of
locations of PAS-positive cells. A P ≤ 0.05 was used to indicate
that the means of two groups were significantly different.
RESULTS
Mouse body weights
The slopes of the linear regression analyses (Table 2) of the mean
body weights (rate of change in body weight) per group for days
1–14 (prior to any drug treatment) were determined to provide
information about the effect of diet on the mouse body weight. The
effect of treatment with CPT-11 on body weight was determined
from the mean body weights for days 14–42 of the study. Results
are shown in Table 2.
Mean tumour size
The mean tumour sizes over the time of treatment are presented
in Figure 1. The slope of the linear regression analyses (tumour
growth rate in mm3 day–1) for the control group which did not
receive CPT-11 was significantly positive (indicating continued
tumour growth, slope = 3.2 ± 0.7) and was significantly different
from the tumour growth rates of the three groups of mice which
received CPT-11. The tumour growth rate of the group of mice
treated with CPT-11 and fed 7% corn oil (slope = –1.8 ± 0.8) was
not significantly different from a slope of zero (indicating that
growth of the tumour was halted by the CPT-11 treatment in this
group of mice) and the tumour growth rate in the 7% corn oil fed
group was significantly different from that of the other three
groups. The mean tumour growth rates of the groups treated with
CPT-11 and fed 3% fish oil (slope = –3.1 ± 0.6) or 6% fish oil
(slope = –3.9 ± 1.0) were:
1. significantly negative, indicating significant regression of the
tumour
2. not significantly different from each other
3. significantly different from the mean tumour growth rate of
the mice which did not receive CPT-11
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Figure 2 Influence of supplementation of the diet with fish oil on alteration
in the distribution of intestinal crypt column heights in the duodenum (A) and
in the descending colon (B) by CPT-11 treatment. Results of the statistical
analyses of these distributions are reported in Table 3444 WE Hardman et al
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4. significantly different from the mean tumour growth rate of the
mice which were treated with CPT-11 and fed 7% corn oil.
Thiobarbituric acid reactive substances
ANOVA revealed that when mice were killed 5 days after treat-
ment with CPT-11, there was not a significant difference in the
nmol TBARS mg–1 protein in the livers of the mice due to treat-
ment with CPT-11 or to the diet of the mice (data not shown).
Tumours of the CPT-11 treated and fish oil fed groups had
regressed to the extent that there was not enough tumour tissue for
TBARS analyses.
Histomorphometric analyses of duodenum and colon
Crypt column heights
Graphs of the distributions of the crypt heights in the duodenum
(Figure 2A) and colon (Figure 2B) illustrate that the mean of the
distribution of crypt heights of the group treated with CPT-11 and
fed 7% corn oil was less than the means of the other three groups.
The distributions of crypt heights of the groups treated with CPT-
11 and fed either 3% or 6% fish oil were similar to that of the
group which did not receive CPT-11 treatment.
ANOVA followed by SNK of the crypt column height data
(Table 3) revealed that, when compared to the control group which
did not receive CPT-11:
1. the mean crypt column heights in the duodenum and colon
were significantly less in mice fed 7% corn oil and treated with
CPT-11
2. the mean crypt column heights in the duodenum and colon
were not significantly less in mice fed 3% fish oil and treated
with CPT-11
3. the mean crypt column height in the colon was not signifi-
cantly less in mice fed 6% fish oil and treated with CPT-11.
ANOVA also revealed that the crypt column heights in both the
duodenum and colon of mice fed either 3% or 6% fish oil and
treated with CPT-11 were significantly greater than in mice fed 7%
corn oil and treated with CPT-11.
Mitotic figures
ANOVA of the numbers of mitotic figures per midaxial crypt
section in the duodenum (Table 4) revealed that there was not
a significant difference between groups. However, ANOVA
followed by SNK of the square root transformed heights of the
mitotic figures revealed that there was a significant difference
between groups in the distribution of mitotic figures in the
duodenum. Specifically, the mean of the distribution of the heights
of mitotic figures in the duodenum of the group treated with CPT-
11 and fed corn oil was significantly less than the mean of the
distribution in the mice which did not receive CPT-11 or in the
mice treated with CPT-11 and fed 3% fish oil. The distribution of
mitotic figures in the duodenum of the groups which were treated
with CPT-11 and fed either 3% or 6% fish oil was similar to the
group which did not receive CPT-11. There were too few mitotic
figures in the histologic sections of colon for meaningful statistical
analysis.
Apoptotic figures
ANOVA followed by SNK revealed that the number of apoptotic
figures per midaxial crypt section in the duodenum of the group
treated with CPT-11 and fed corn oil was significantly higher than
in the control group which did not receive CPT-11 (Table 4). The
mean number of apoptotic figures in the groups treated with CPT-
11 and fed either 3% or 6% fish oil was intermediate and not
significantly different from either the control group which did not
receive CPT-11 or the group treated with CPT-11 and fed corn oil.
The mean height of the distribution of apoptotic figures in the
duodenum of the group treated with CPT-11 and fed corn oil was
significantly less than the mean of that distribution in the mice
which did not receive CPT-11 or in the mice treated with CPT-11
and fed 3% fish oil, as summarized in Table 4. There were too few
apoptotic figures in the histologic sections of colon for meaningful
statistical analysis.
Table 3 Influence of dietary fish oil on alteration of intestinal crypt column
heighta by CPT-11 treatment
Diet CPT-11 nb Duodenum nb Colon
5 mice per group mean ± s.d. mean ± s.d.
Chow – 92 23.5 ± 5.0d 70 25.0 ± 4.0c
7% Corn oil + 90 17.1 ± 4.0 66 20.1 ± 4.5
3% Fish oil + 74 22.6 ± 2.6d 56 23.7 ± 3.3c
6% Fish oil + 64 21.0 ± 3.2c 23 23.3 ± 3.8c
aCrypt column height is expressed in number of cells from the base to the
mouth of the crypt. bn = total number of crypt columns counted per group.
c,dANOVA followed by SNK multiple range test showed that means which
share a superscript in a column are not significantly different.
Table 4 Influence of CPT-11 treatment dietary fish oil on the number and the location of mitotic and apoptotic figures in duodenum crypts
Diet CPT N Mitotic Trans. height N Apoptotic Trans. height
5 mice/per –11 mitotic figures per mitotic apoptotic figures per cryptb apoptotic
group figuresa cryptb figuresb figuresa figuresc
Chow – 101 2.2 ± 1.5d 3.1 ± 0.9d 52 0.46 ± 0.19d 2.79 ± 0.95d
Corn oil, + 93 2.1 ± 1.5d 2.5 ± 0.7e 58 1.14 ± 0.49e 2.03 ± 0.76e
3% Fish oil + 73 2.6 ± 1.7d 2.9 ± 0.8d 88 0.74 ± 0.22de 2.76 ± 0.81d
6% Fish oil + 40 2.0 ± 0.9d 2.6 ± 0.6e 80 0.90 ± 0.28de 2.30 ± 0.83e
aTotal number of mitotic or apoptotic figures counted per group. bMean number of mitotic or apopotic figures per midaxial crypt section (mean ± s.d.). cMean of
the square root transformed heights of mitotic or apoptotic figures (mean ± s.d.). deMeans that share the same superscript in a column are not significantly
different.Fish oil, CPT-11 and breast cancer 445
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PAS+ goblet cells
ANOVA followed by SNK revealed that the mean number of PAS+
goblet cells per colon crypt column in the group of mice treated
with CPT-11 and fed the 7% corn oil diet (Table 5) was signifi-
cantly higher than in the group of mice which did not receive CPT-
11. However, in the groups of mice fed the 3% or 6% fish oil diet
and treated with CPT-11, the mean number of PAS+ goblet cells
per colon crypt was not significantly different from that of the
control group of mice which did not receive CPT-11. Examples of
these findings are depicted in the photomicrographs in Figure 3.
The mean height of PAS+ goblet cells in the colon crypts was
significantly lower in all groups of mice treated with CPT-11 than
in the group of mice not treated with CPT-11.
Statistical analyses by ANOVA followed by SNK revealed that
in groups of mice treated with CPT-11, the mean number of goblet
cells per crypt column in the duodenum (Table 5) was significantly
less than in the mice which did not receive CPT-11. However, the
mean height of PAS+ goblet cells in the duodenum crypts of mice
fed 7% corn oil or 3% fish oil diets and treated with CPT-11 was
not significantly different from that of the control group of mice
which did not receive CPT-11.
Thickness of muscularis mucosa
Statistical analysis by ANOVA followed by SNK revealed that the
thickness of the muscularis mucosa layer in the colons of mice
treated with CPT-11 and fed the diet containing 6% fish oil
Table 5 Influence of dietary fish oil on alteration of number and distribution of PAS+ goblet cells in descending colon crypts by CPT-11 treatment
Descending colon Duodenum
Diet CPT Number Mean (± s.d.) Mean (± s.d.) Number Mean (± s.d.) Mean (± s.d.)
n=5 –11 goblet goblet cells/ height of goblet goblet height of
mice/group cells per crypt  goblet cells in cells cells per crypt goblet cells in
scored columna crypt scored columna crypt
Chow – 88 5.5 ± 1.8c 16.4 ± 6.2b 73 2.4 ± 1.3b 13.6 ± 6.0b
7% Corn oil + 107 8.2 ± 2.7b 13.1 ± 6.2c 30 1.3 ± 0.6c,d 12.1 ± 3.7b,c
3% Fish oil + 89 5.6 ± 1.9c 13.2 ± 6.3c 40 1.7 ± 1.3c 11.4 ± 4.2b,c
6% Fish oil + 78 5.3 ± 2.4c 11.5 ± 5.5c 24 1.0 ± 1.0d 10.3 ± 3.6c
aMean number of goblet cells per crypt column scored in midaxially sectioned crypts. b,c,dColumn means that share the same superscript are not significantly
different.
ABC
Bar = 40 mm
Control no CPT-11 Corn oil with CPT-11 Fish oil with CPT-11
Bar = 40 mm
Figure 3 Photomicrographs of histologic sections of the descending colon mucosa of female nude (nu/nu) mice. Sections were stained by the periodic acid-
Schiff (PAS) reaction and counterstained with haematoxylin. The crypts pictured are representative of crypts from mice fed: (A) the mouse chow diet and not
treated with CPT-11; (B) the 7% corn oil diet for 2 weeks prior to and during the course of CPT-11 treatment (60 mg kg–1 body weight, i.v. q4d 3 6); (C) the 3%
fish oil and 4% corn oil diet prior to and during the same course of CPT-11 treatment. Mice were killed 5 days after the last injection of CPT-11. The
magnification of each photomicrograph is the same allowing visual comparison of crypt heights and of the distribution and size of the PAS+ goblet cells. Notice
that crypts are shorter and that there is goblet cell hyperplasia in the photomicrograph of a colon section from a mouse fed 7% corn oil diet and treated with
CPT-11 (4-mm-thick sections, bar = 40 mm)446 WE Hardman et al
British Journal of Cancer (1999) 81(3), 440–448 © 1999 Cancer Research Campaign
(10.8 ± 0.2 mm) was not significantly different from that of the
mice not treated with CPT-11 (11.1 ± 0.3 mm). However, the thick-
ness of the muscularis mucosa layer in the colons of mice fed 7%
corn oil and treated with CPT-11 (6.6 ± 0.2 mm) was significantly
less than in the mice not treated with CPT-11 or the mice fed 6%
fish oil and treated with CPT-11. The thickness of the muscularis
mucosa layer in the colons of mice fed 3% fish oil and treated with
CPT-11 (7.7 ± 0.2 mm) was intermediate in thickness but was not
significantly different from the mean value of the other groups.
The muscularis mucosa layer in the duodenum of all groups was
too thin for reliable measurements.
DISCUSSION
Results from the present study demonstrate that 60 mg CPT-11 per
kg body weight (i.v. q4d 3 6) halted the growth of, but did not
cause significant regression of, MCF7 human breast carcinoma
xenografts in groups of mice fed a diet containing 7% corn oil.
However, when the diet of the mice was supplemented with 3% or
6% fish oil, the same CPT-11 treatment caused a significant regres-
sion of the MCF7 xenograft. All of the tumours in the mice fed fish
oil regressed to the extent that there was not sufficient tumour
tissue to investigate mechanisms contributing to the regression
(i.e. lipid peroxidation) as we did in earlier studies (Hardman et al,
1997). Because of this fact, we could not test the hypothesis that
the combination of dietary fish oil and CPT-11 administration
leads to the selective accumulation of lipid peroxidation products
to cytotoxic levels in the MCF7 xenograft. As in the earlier study
(Hardman et al, 1997), dietary fish oil did not significantly
increase potentially cytotoxic lipid peroxidation products in the
host liver.
In addition to enhancing the efficacy of CPT-11 against growth
of MCF7 human breast carcinoma xenografts, supplementation of
the diet with 3% or with 6% w/w fish oil resulted in amelioration
of the intestinal damage resulting from CPT-11 treatment. To eval-
uate the intestinal damage resulting from CPT-11 treatment, we
examined intestinal mucosa taken from mice treated with CPT-11
(60 mg kg–1 q4d 3 6) and killed 5 days after the last injection. The
dosage of CPT-11 used in our study was less than that used in prior
studies and the tissues were removed for study at a longer duration
after the last dose of CPT-11 than in prior studies (Ikuno et al,
1995; Cao et al, 1998; Shinohara et al, 1998). Thus, we examined
longer term changes in intestinal mucosa following administration
of more clinically relevant doses than previous studies. In mice
treated with CPT-11 and fed the 7% corn oil diet, we found that
there was a significant (P < 0.05) shortening in crypt heights in the
duodenum accompanied by a significant decrease in number of
goblet cells, a significant increase in number of apoptotic cells and
a significant decrease in the size (height) of the cell proliferation
compartment compared to mice which did not receive CPT-11.
Increased apoptotic death in the CPT-11 treated mice fed corn oil,
which was not accompanied by increased mitotic activity in the
crypt epithelium, may help account for the decreased number of
cells in the duodenum crypt column.
In the colon of CPT-11 treated mice fed 7% corn oil, the muscu-
laris mucosa was significantly thinner, the mean crypt column
height was significantly shorter and the shorter column height was
accompanied by a significant increase in number of goblet cells
than in the colon of mice not treated with CPT-11. Specifically, the
number of goblet cells in the colon crypt column increased by 49%
(hyperplasia) but the number of non-goblet cells (mainly columnar
absorptive cells) was decreased by 39% following treatment with
CPT-11. The reduction in the number of columnar absorptive cells
in the colon may help account for the reported malabsorption of
water and electrolytes in the large bowel of CPT-11-treated indi-
viduals (Kase et al, 1997a).
Not only were there more goblet cells in the colon crypt column
of mice treated with CPT-11 and fed corn oil than in those which
did not receive CPT-11, but the distribution of goblet cells was
shifted towards the base of the colon crypts and the goblet cells
tended to be larger as illustrated in Figure 3. The presence of larger
goblet cells indicates that CPT-11 treatment caused accumulation
of mucous secretory granules in the goblet cells. Increased accu-
mulation of mucus could be due to a failure of the goblet cells to
secrete the mucous granules and/or due to an increased synthesis
of mucus. Regardless, we can state that a diet which included fish
oil prevented CPT-11-induced goblet cell hyperplasia in the colon
but did not prevent the shift of the distribution of goblet cells
towards the base of colon crypts.
In a past report (Ikuno et al, 1995), goblet cell hyperplasia in the
cecum was attributed to induction of differentiation of goblet cells by
CPT-11. Our findings of goblet cell hypoplasia in the duodenum of
mice fed 7% corn oil indicates that CPT-11 failed to induce a greater
number of differentiated goblet cells in the duodenum, thus the cells
of the small and large intestine responded differently to CPT-11 treat-
ment. Further research is needed to understand the effect of CPT-11
treatment on goblet cell differentiation and the effect of the alteration
in the goblet cell population on colon function.
Taken together, the histological changes in muscularis mucosa
thickness, numbers of absorptive and goblet cells per midaxial
crypt column and goblet cell size, as described here, indicate that
CPT-11 treatment induced structural changes in the intestinal
mucosa of mice fed 7% corn oil which persisted at least 5 days
following the last dose of CPT-11. On the other hand, the intestinal
mucosal architecture of mice that were treated with CPT-11 and fed
the diets containing fish oil was largely the same as the intestinal
mucosal architecture of the mice not treated with CPT-11.
Diarrhoea is a dose-limiting side-effect of CPT-11 treatment,
thus, attempts have been made to understand the causes of the
severe diarrhoea induced by CPT-11 treatment (Sawada et al,
1991; Sakai et al, 1995, 1997; Rothenberg, 1996; Kase et al,
1997b; Shinohara et al, 1998). There are various causes of
diarrhoea including: hyperperistalsis, malabsorption of water and
electrolytes and/or hypersecretion of Cl–. Although the exact
mechanism of CPT-11-induced diarrhoea is not defined, several
approaches have been explored to overcome the toxicity of
CPT-11 to the intestines, including:
1. The use of the bacterial lipopeptide (JBT 3002), to stimulate
intestinal mucosal immunity and to help maintain mucosal
architecture (Shinohara et al, 1998). In this regard, Shinohara
et al (1998) reported that treatment of mice with CPT-11 (i.p.
100 mg kg–1 q4d) was effective against liver metastasis of the
CT-26 murine colon cancer in a syngeneic mouse model. They
also reported that oral administration of JBT 3002 prior to the
same treatment with CPT-11 resulted in: increased inhibition
of liver metastasis, reduced mouse mortality and reduced
damage to the mouse intestines (Shinohara et al, 1998) and
proposed that the mechanism of action of JBT 3002 was via its
modulation of immune activity. Likewise, Cao et al (1998)
demonstrated that use of interleukin 15 offered protection
against CPT-11 induced intestinal damage and suggested thatthe mechanism for protection was by immunomodulation
(Cao et al, 1998).
2. The inhibition of thromboxane A2 (TXA2) synthesis, blocking
of TXA2 receptors (Sakai et al, 1997) or the use of various
drugs to inhibit prostaglandins E2 (PGE2) and F2 (PGE2) to
inhibit the ability of these eicosanoids to stimulate CI– secre-
tion and decrease water absorption in the colon (Sakai et al,
1995; Kase et al, 1997b).
3. The use of an inhibitor of the conversion of CPT-11 to SN-38,
its more active metabolite (Narita et al, 1993).
4. The use of drugs including atropine or loperamide. Atropine
decreases intestinal motility (peristalsis) by blocking the
activity of acetylcholine (Takasuna et al, 1995; Mosby’s
Complete Drug Reference, 1997a). Loperamide acts to slow
intestinal motility and affects water and electrolyte movement
through the bowel (Mosby’s Complete Drug Reference,
1997b). High-dose loperamide has been used effectively to
treat CPT-11-induced diarrhoea (Abigerges et al, 1994).
However, loperamide at 50 mmol l–1 has been shown to reduce
the conversion of CPT-11 to SN-38 (the active metabolite) in
vitro which may interfere with CPT-11 anticancer action
(Rivory et al, 1996b). The effect of loperamide on the efficacy
of CPT-11 in vivo is not known (Rivory, 1996a).
5. The use of antibiotics to reduce the effects of infection and
loss of intestinal integrity and normal function (Takasuna et al,
1996).
To this list, we now add use of dietary fish oil supplementation.
The amount of fish oil needed to normalize intestinal mucosal
structure and function and how fish oil may work are discussed in
the next two sections.
Relevance of consumption by mice of 3% or 6% w/w
dietary fish oil to humans
It has been reported (Anti et al, 1992; Horrobin, 1994) that adult
humans can consume about 10–12 g of fish oil per day without
adverse side-effects. We have personally verified that taking this
amount of encapsulated fish oil per day for at least 2 months
caused no ill effects. How does consumption of 10–12 g fish oil
per day by humans compare to the 3% and 6% fish oil diets fed to
the mice in this study?
At nine calories per g of fat, 10 g of fish oil contains 90 calories.
Therefore for a person consuming 1800 calories per day, 10 g of
fish oil in the diet would be 90/1800 = 5% of calories from fish oil.
Each 100 g of the 7% fat mouse diet supplied 395 calories.
Therefore, in the 3% w/w fish oil diet, 3 g per 100 g of the diet was
fish oil. It follows that fish oil accounted for 27/395 or 6.8% of
calories in the mouse diet. These calculations show that the 3%
fish oil diet is in a range which humans can easily consume by
supplementation of the diet with 10–12 g of fish oil per day.
Relevance of fish oil supplementation on prostaglandin
synthesis in colon
Increased concentrations of PGE2 and TXA2 in the large bowel
have been associated with increased Cl– secretion and diarrhoea
resulting from CPT-11 administration (Kase et al, 1997b; Sakai et
al, 1997). The types of eicosanoids produced by cells are readily
modified based on the precursor fatty acids which are available for
eicosanoid synthesis (Weber and Sellmayer, 1990). When n-3 fatty
acids are consumed in the diet, eicosapentanoic acid, which is the
substrate for synthesis of n-3 derived eicosanoids such as PGE3 and
TXA3, is proportionately increased in the phospholipids of cellular
membranes (Anti et al, 1992) while arachidonic acid, which is the
substrate for synthesis of n-6 derived eicosanoids such as PGE2 and
TXA2, is decreased. Indeed, as little as 4.4 g of n-3 fatty acids per
day significantly increased EPA, decreased arachidonic acid
and decreased the PGE2 in colonic mucosa of healthy volunteers
(Bartram et al, 1993). Thus suppression of PGE2 and TXA2
synthesis by consumption of dietary n-3 FA would be expected to
decrease the diarrhoea induced by eicosanoid mediated Cl–secre-
tion and would be expected to decrease the diarrhoea associated
with CPT-11 treatment. Evaluation of the effect of dietary n-3 fatty
acid consumption on stimulation of eicosanoid synthesis as a result
of CPT-11 treatment warrants further investigation.
Implication
Regardless of the need for additional research on the specific
mechanism for activity, we believe that the results of our current
preclinical trial, using dietary fish oil supplementation in combina-
tion with CPT-11, are sufficient to recommend the initiation of
clinical testing of dietary supplementation with fish oil as an effec-
tive, non-toxic and inexpensive method to decrease or prevent
severe diarrhoea in cancer patients and to increase the efficacy of
the anticancer drug, CPT-11.
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